Table 2.
Odds Ratio for Association Between Partner Bereavement and Herpes Zoster
| Bereavement Status | Denmark | United Kingdom | ||||||
|---|---|---|---|---|---|---|---|---|
| Case Patients, No. (%) | Controls, No. (%) | Unadjusted OR (99% CI) | Adjusted OR (99% CI)a | Case Patients, No. (%) | Controls, No. (%) | Unadjusted OR (99% CI) | Adjusted OR (99% CI)a | |
| Never bereaved | 157076 (82.4) | 633082 (83.0) | Reference | Reference | 141774 (94.4) | 544495 (94.4) | Reference | Reference |
| Bereaved, by duration of bereavement | ||||||||
| Total | 33595 (17.6) | 129602 (17.0) | 1.06 (1.04–1.08) | 1.05 (1.03–1.07) | 8433 (5.6) | 32383 (5.6) | 1.01 (.98–1.05) | 1.01 (.98–1.05) |
| 0–7 d | 26 (0.01) | 159 (0.02) | 0.66 (.38–1.15) | 0.67 (.38–1.15) | 16 (0.01) | 77 (0.01) | 0.81 (.40–1.64) | 0.82 (.40–1.67) |
| 8–14 d | 31 (0.02) | 126 (0.02) | 1.00 (.60–1.68) | 1.03 (.61–1.73) | 13 (0.01) | 74 (0.01) | 0.69 (.32–1.50) | 0.69 (.32–1.50) |
| 15–30 d | 90 (0.05) | 367 (0.05) | 1.00 (.73–1.35) | 1.01 (.74–1.37) | 52 (0.03) | 165 (0.03) | 1.24 (.82–1.87) | 1.26 (.84–1.91) |
| 31–90 d | 343 (0.2) | 1273 (0.2) | 1.09 (.94–1.28) | 1.10 (.94–1.29) | 171 (0.1) | 629 (0.1) | 1.06 (.85–1.32) | 1.05 (.84–1.32) |
| 91–365 d | 1572 (0.8) | 5977 (0.8) | 1.07 (.99–1.15) | 1.07 (.99–1.15) | 746 (0.5) | 2956 (0.5) | 0.98 (.88–1.09) | 0.98 (.88–1.09) |
| 366–1095 d | 3989 (2.1) | 15322 (2.0) | 1.06 (1.01–1.11) | 1.06 (1.01–1.11) | 1755 (1.2) | 6712 (1.2) | 1.02 (.95–1.09) | 1.02 (.95–1.09) |
| >1095 d | 27544 (14.4) | 106378 (13.9) | 1.06 (1.03–1.08) | 1.05 (1.03–1.07) | 5680 (3.8) | 21770 (3.8) | 1.02 (.97–1.06) | 1.01 (.97–1.05) |
Abbreviations: CI, confidence interval; OR, odds ratio.
aAdjusted for rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, diabetes, chronic kidney disease, human immunodeficiency virus infection, hematopoietic stem cell/bone marrow transplantation, solid organ transplantation, other cellular immune deficiency, leukemia, lymphoma, myeloma, oral glucocorticoids, other immunosuppressant drugs, and inhaled glucocorticoids.